Institutional members access full text with Ovid®

Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock*

Nakada, Taka-aki MD, PhD; Russell, James A. MD, FRCP(C); Boyd, John H. MD, FRCP(C); McLaughlin, Luke BSc; Nakada, Emiri MD; Thair, Simone A. BSc; Hirasawa, Hiroyuki MD, PhD; Oda, Shigeto MD, PhD; Walley, Keith R. MD, FRCP(C)

doi: 10.1097/CCM.0b013e318218665a
Clinical Investigations

Objective: Angiotensin II and its postreceptor signaling are crucial in regulating vasomotor tone. The objective of this study was to test the hypothesis that single nucleotide polymorphisms in angiotensin II pathway genes alter outcome of septic shock.

Design: Genetic association study and in vitro experiment.

Setting: Intensive care units at academic teaching centers.

Patients: Derivation and validation septic shock cohorts (n = 589 and n = 616, respectively) and a coronary artery bypass surgery cohort (n = 551).

Interventions: Patients with septic shock in the derivation cohort were genotyped for tag single nucleotide polymorphisms: angiotensin-converting enzyme (six single nucleotide polymorphisms), angiotensin II receptor type 1 (five single nucleotide polymorphisms), and angiotensin II type 1 receptor-associated protein (three single nucleotide polymorphisms), which is a negative regulator of angiotensin II receptor type 1. Patients in the septic shock replication cohort and the coronary artery bypass graft cohort were genotyped for the angiotensin II type 1 receptor-associated protein rs11121816.

Measurements and Main Results: The primary outcome variable was 28-day mortality. Secondary outcome variables were blood pressure and heart rate. Angiotensin II type 1 receptor-associated protein messenger RNA expression was measured in genotyped lymphoblastoid cells in vitro. Patients with septic shock patients the GG genotype of angiotensin II type 1 receptor-associated protein rs11121816 had increased 28-day mortality in the derivation cohort (54.8% vs. 41.4%; adjusted hazard ratio, 1.46; 95% confidence interval, 1.09–1.93; p = .010 [all ethnicities]; p = .050 [white]) and in the replication cohort (43.8% vs. 32.3%; hazard ratio, 1.42; 95% confidence interval, 1.03–1.98; p = .035 [all ethnicities]; p = .037 [white]). Patients having the GG genotype had decreased mean arterial pressure (98.3% of other genotype, p = .058 [derivation cohort]; 97.7%, p = .00060 [replication cohort]) and increased heart rate (104.1%, p = .023 [derivation cohort], 102.9%, p = nonsignificant [replication cohort]). GG genotype patients undergoing coronary artery bypass grafting had decreased postoperative mean arterial pressure and increased postoperative heart rate (p < .05). GG genotype lymphoblastoid cells had 2.0-fold higher angiotensin II type 1 receptor-associated protein messenger RNA expression (p < .05).

Conclusions: For angiotensin II type 1 receptor-associated protein, the negative regulator of angiotensin II receptor type 1, the GG genotype of rs11121816 was associated with increased angiotensin II type 1 receptor-associated protein expression, decreased blood pressure, and increased heart rate as well as increased 28-day mortality in septic shock.

From the University of British Columbia (TN, JAR, JHB, LM, EN, SAT, KRW), Critical Care Research Laboratories, Heart + Lung Institute, St Paul's Hospital, Vancouver, British Columbia, Canada; and the Chiba University Graduate School of Medicine (HH, SO), Department of Emergency and Critical Care Medicine, Inohana, Chuo, Chiba, Japan.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ccmjournal.com).

Support provided by the Heart and Stroke Foundation. Dr. Nakada is an IMPACT Postdoctoral Fellow and supported in part by a research fellowship from Yamada Science Foundation. Genotyping was supported by Sirius Genomics Inc. Dr. Russell consulted for Sirius Genomics and received honoraria/speaking fees from Eli Lilly, Pfizer, Ferring, and AstraZeneca. Dr. Russell also holds stock ownership and stock options in Sirius Genomics. Dr. Walley holds stock options and stock ownership in Sirius Genomics. Drs. Russell and Walley received University of British Columbia patents for Protein C, vasopressin, and NIK. The remaining authors have not disclosed any potential conflicts of interest.

For information regarding this article, E-mail: Keith.Walley@hli.ubc.ca

© 2011 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins